Skip to main content
Top
Published in: BMC Endocrine Disorders 1/2024

Open Access 01-12-2024 | Type 2 Diabetes | Research

Elevated serum CA199 levels in patients suffering type 2 diabetes vs. various types of cancer

Authors: Yong Zhuang, Qingyan Cai, Xin Hu, Huibin Huang

Published in: BMC Endocrine Disorders | Issue 1/2024

Login to get access

Abstract

Aims

Carbohydrate antigen 199 (CA199) is a standard tumor marker, and recent studies have found elevated in CA199 levels in patients with diabetes. However, there is no systematic measurement and comparison of serum CA199 levels in patients with diabetes and cancer. Here, a detailed description of the changes in serum CA199 levels in patients with type 2 diabetes and various cancers was explored.

Methods

A total of 5,641 participants were screened for clinical laboratory test results of serum CA199 levels over the past three years (2020–2023). This study included 2,464 healthy controls, 688 patients with type 2 diabetes, and 2,489 patients with 16 different types of cancer. Each type of cancer had more than 30 independent serum CA199 level test results. The serum CA199 levels were compared between cancer groups, type 2 diabetes patients, and healthy controls. Additionally, the CA199 levels of cancer patients were compared with those of patients with type 2 diabetes.

Results

The serum CA199 levels of esophagus cancer, lung cancer, pancreatic cancer, ovarian cancer, breast cancer, rectum cancer, prostate cancer, bladder cancer, liver cancer, gastric cancer, cervical cancer, colon cancer, lymphoma, thyroid cancer, intracranial tumors, and nasopharyngeal laryngeal cancer were found to be elevated compared to healthy controls (P < 0.01). In addition, the serum CA199 levels of patients with type 2 diabetes were also significantly elevated compared to healthy controls (P < 0.01). Moreover, the degree of elevation in serum CA199 levels in patients with type 2 diabetes was not significantly different from that observed in some types of cancer, such as esophagus cancer (P = 0.163), breast cancer (P = 0.927), prostate cancer (P = 1.000), bladder cancer (P = 0.406), Lymphoma (P = 0.975), thyroid cancer (P = 1.000), intracranial tumors (P = 0.161), nasopharyngeal and laryngeal cancer (P = 1.000).

Conclusions

Serum CA199 levels also increase in type 2 diabetes, and the magnitude of the increase is similar to that seen in some cancers.
Appendix
Available only for authorised users
Literature
1.
go back to reference Koprowski H, Steplewski Z, Mitchell K, et al. Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet. 1979;5(6):957–71.CrossRefPubMed Koprowski H, Steplewski Z, Mitchell K, et al. Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet. 1979;5(6):957–71.CrossRefPubMed
2.
go back to reference Zhang M, Dou H, Yang D, et al. Retrospective analysis of glycan-related biomarkers based on clinical laboratory data in two medical centers during the past 6 years. Prog Mol Biol Transl Sci. 2019;162:141–63.CrossRefPubMed Zhang M, Dou H, Yang D, et al. Retrospective analysis of glycan-related biomarkers based on clinical laboratory data in two medical centers during the past 6 years. Prog Mol Biol Transl Sci. 2019;162:141–63.CrossRefPubMed
3.
go back to reference Zeng P, Li H, Chen Y, et al. Serum CA199 levels are significantly increased in patients suffering from liver, lung, and other diseases. Prog Mol Biol Transl Sci. 2019;162:253–64.CrossRefPubMed Zeng P, Li H, Chen Y, et al. Serum CA199 levels are significantly increased in patients suffering from liver, lung, and other diseases. Prog Mol Biol Transl Sci. 2019;162:253–64.CrossRefPubMed
4.
go back to reference Sun H, Saeedi P, Karuranga S, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119.CrossRefPubMed Sun H, Saeedi P, Karuranga S, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119.CrossRefPubMed
5.
go back to reference Zhang D, Hou W, Liu F, et al. Metformin reduces serum CA199 levels in type 2 diabetes Chinese patients with time-effect and gender difference. Diabetes Technol Ther. 2015;17(2):72–9.CrossRefPubMedPubMedCentral Zhang D, Hou W, Liu F, et al. Metformin reduces serum CA199 levels in type 2 diabetes Chinese patients with time-effect and gender difference. Diabetes Technol Ther. 2015;17(2):72–9.CrossRefPubMedPubMedCentral
6.
go back to reference Du ZX, Liang MM, Sun J et al. Clinical significance of serum CA-125, CA19-9 and CEA in pulmonary tuberculosis with and without type 2 diabetes. Tuberculosis (Edinb). 2017;107:104–110.of diabetes prevalence for 2017 and projections for 2045. Diabetes Res. Du ZX, Liang MM, Sun J et al. Clinical significance of serum CA-125, CA19-9 and CEA in pulmonary tuberculosis with and without type 2 diabetes. Tuberculosis (Edinb). 2017;107:104–110.of diabetes prevalence for 2017 and projections for 2045. Diabetes Res.
7.
go back to reference Cho NH, Shaw JE, Karuranga S et al. IDF Diabetes atlas: global estimates Clin Pract. 2018;138:271–81. Cho NH, Shaw JE, Karuranga S et al. IDF Diabetes atlas: global estimates Clin Pract. 2018;138:271–81.
8.
go back to reference Rowbottom L, Stinson J, McDonald R, et al. Retrospective review of the incidence of monitoring blood glucose levels in patients receiving corticosteroids with systemic anticancer therapy. Ann Palliat Med. 2015;4(2):70–7.PubMed Rowbottom L, Stinson J, McDonald R, et al. Retrospective review of the incidence of monitoring blood glucose levels in patients receiving corticosteroids with systemic anticancer therapy. Ann Palliat Med. 2015;4(2):70–7.PubMed
9.
go back to reference Tsilidis KK, Kasimis JC, Lopez DS, et al. Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. BMJ. 2015;350:g7607.CrossRefPubMed Tsilidis KK, Kasimis JC, Lopez DS, et al. Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. BMJ. 2015;350:g7607.CrossRefPubMed
10.
go back to reference DeCensi A, Puntoni M, Gandini S, et al. Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial. Breast Cancer Res Treat. 2014;148(1):81–90.CrossRefPubMedPubMedCentral DeCensi A, Puntoni M, Gandini S, et al. Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial. Breast Cancer Res Treat. 2014;148(1):81–90.CrossRefPubMedPubMedCentral
11.
go back to reference Aldakkak M, Christians KK, Krepline AN, et al. Pre-treatment carbohydrate antigen 19– 9 does not predict the response to neoadjuvant therapy in patients with localized pancreatic cancer. HPB (Oxford). 2015;17(10):942–52.CrossRefPubMed Aldakkak M, Christians KK, Krepline AN, et al. Pre-treatment carbohydrate antigen 19– 9 does not predict the response to neoadjuvant therapy in patients with localized pancreatic cancer. HPB (Oxford). 2015;17(10):942–52.CrossRefPubMed
12.
go back to reference Liu X, Cai H, Wang Y. Prognostic significance of tumour markers in Chinese patients with gastric cancer. ANZ J Surg. 2014;84(6):448–53.CrossRefPubMed Liu X, Cai H, Wang Y. Prognostic significance of tumour markers in Chinese patients with gastric cancer. ANZ J Surg. 2014;84(6):448–53.CrossRefPubMed
13.
go back to reference Li A, Tan Z, Fu C, et al. Analysis of risk factors for bone metastasis after radical resection of colorectal cancer within 5 years. Zhonghua Wei Chang Wai Ke Za Zhi. 2017;20(1):58–61.PubMed Li A, Tan Z, Fu C, et al. Analysis of risk factors for bone metastasis after radical resection of colorectal cancer within 5 years. Zhonghua Wei Chang Wai Ke Za Zhi. 2017;20(1):58–61.PubMed
14.
go back to reference Liu Y, Sun J, Zhang Q, et al. Identification of bile survivin and carbohydrate antigen 199 in distinguishing cholangiocarcinoma from benign obstructive jaundice. Biomark Med. 2017;11(1):11–8.CrossRefPubMed Liu Y, Sun J, Zhang Q, et al. Identification of bile survivin and carbohydrate antigen 199 in distinguishing cholangiocarcinoma from benign obstructive jaundice. Biomark Med. 2017;11(1):11–8.CrossRefPubMed
15.
go back to reference Tong W, Gao H, Wei X, et al. Correlation of serum CA199 levels with glycemic control and microvascular complications in patients with type 2 diabetes mellitus. Am J Transl Res. 2021;13(4):3302–8.PubMedPubMedCentral Tong W, Gao H, Wei X, et al. Correlation of serum CA199 levels with glycemic control and microvascular complications in patients with type 2 diabetes mellitus. Am J Transl Res. 2021;13(4):3302–8.PubMedPubMedCentral
16.
go back to reference Cai R, Kong Q, Wang Z, et al. Correlation between tumor markers and type 2 diabetes mellitus complications and their related influencing factors. Ann Palliat Med. 2022;11(1):58–67.CrossRefPubMed Cai R, Kong Q, Wang Z, et al. Correlation between tumor markers and type 2 diabetes mellitus complications and their related influencing factors. Ann Palliat Med. 2022;11(1):58–67.CrossRefPubMed
17.
go back to reference Jiang Q, Lei L, Zhang X, et al. The correlated factors of serum CA19-9 levels in Diabetic patients. Curr Diabetes Rev. 2017;13(1):47–9.CrossRefPubMed Jiang Q, Lei L, Zhang X, et al. The correlated factors of serum CA19-9 levels in Diabetic patients. Curr Diabetes Rev. 2017;13(1):47–9.CrossRefPubMed
18.
go back to reference Donath MY, Schumann DM, Faulenbach M, et al. Islet inflammation in type 2 diabetes: from metabolic stress to therapy. Diabetes Care. 2008;31(Suppl 2):161–4.CrossRef Donath MY, Schumann DM, Faulenbach M, et al. Islet inflammation in type 2 diabetes: from metabolic stress to therapy. Diabetes Care. 2008;31(Suppl 2):161–4.CrossRef
19.
go back to reference Lenoir D, Gréco S, Louisot P, et al. Implication of insulin and nutritional factors in the regulation of intestinal galactosyltransferase activity during postnatal development. Metabolism. 2000;49(4):526–31.CrossRefPubMed Lenoir D, Gréco S, Louisot P, et al. Implication of insulin and nutritional factors in the regulation of intestinal galactosyltransferase activity during postnatal development. Metabolism. 2000;49(4):526–31.CrossRefPubMed
20.
go back to reference Shiraishi N, Natsume A, Togayachi A, et al. Identification and characterization of three novel beta 1,3-N-acetylglucosaminyltransferases structurally related to the beta 1,3-galactosyltransferase family. J Biol Chem. 2001;276(5):3498–507.CrossRefPubMed Shiraishi N, Natsume A, Togayachi A, et al. Identification and characterization of three novel beta 1,3-N-acetylglucosaminyltransferases structurally related to the beta 1,3-galactosyltransferase family. J Biol Chem. 2001;276(5):3498–507.CrossRefPubMed
21.
go back to reference Murai J, Soga S, Saito H, et al. Study on the mechanism causing elevation of serum CA19-9 levels in diabetic patients. Endocr J. 2013;60(7):885–91.CrossRefPubMed Murai J, Soga S, Saito H, et al. Study on the mechanism causing elevation of serum CA19-9 levels in diabetic patients. Endocr J. 2013;60(7):885–91.CrossRefPubMed
Metadata
Title
Elevated serum CA199 levels in patients suffering type 2 diabetes vs. various types of cancer
Authors
Yong Zhuang
Qingyan Cai
Xin Hu
Huibin Huang
Publication date
01-12-2024

Other articles of this Issue 1/2024

BMC Endocrine Disorders 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.